Home > Boards > US Listed > Medical - Drugs >

TrovaGene, Inc. (TROV)

TROV RSS Feed
Add TROV Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 3/27/2020 8:10:22 PM - Followers: 73 - Board type: Free - Posts Today: 0

Trovagene logoTrovagene, Inc. 
11055 Flintkote Ave., Suite B
San Diego, CA 92121
USA
 
Tel: USA [+1] 858 217 4838
Fax: USA [+1] 858 217 4768 
E-mail:  service@trovagene.com
http://trovagene.com/
 
TrovaGene, Inc. is a publicly traded company molecular diagnostics company, with headquarters in San Diego, California. We are dedicated to the development and commercialization of unique, proprietary, molecular in-vitro diagnostics technologies. 
The company's founding scientists were the first to report that cell free fragments of DNA from normal cell death that circulate in the blood can cross the kidney barrier and be detected in urine. 
These cell-free nucleic fragments that pass through the kidney ("transrenal" or Tr-DNA/RNA) can be used as genetic markers of disease. The company believes that this transrenal technology will open significant new markets in the molecular diagnostics field and lead to improvements in the area of personalized medicine.

TroveGene, Inc. news

Attention: Gabriele Cerrone, Director of Trovagene
 
Gabriele Cerrone, Founder and Chairman of FermaVir Pharmaceuticals.
FermaVir Pharmaceuticals was bought out by Inhibitex (INHX) in 2007 and Gabriele Cerrone was appointed a Director of the acquiring company.
Bristol-Myers Squibb offered $2.5 Billion to acquire Inhibitex.

Bristol-Myers Squibb to Acquire Inhibitex

InhibitexReleased: 01/07/12 09:13 PM EST
Bristol-Myers Squibb Company (NYSE:BMY) and Inhibitex, Inc. (Nasdaq:INHX) announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger. The transaction, with an aggregate purchase price of approximately $2.5 billion, has been approved by the boards of directors of both companies. The board of directors of Inhibitex has agreed to recommend that Inhibitex's shareholders tender their shares in the tender offer. In addition, shareholders with beneficial ownership of approximately 17% of Inhibitex's common stock have entered into agreements with Bristol-Myers Squibb to support the transaction and to tender their shares in the tender offer.

Gabriele Cerrone holds an 11.4% interest in Trovagene.

Highlights:

Trovagene Closes Acquisition of CLIA Laboratory Assets
 
SAN DIEGO, Feb. 8, 2012 /PRNewswire/ -- Trovagene, Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, today announced that it has closed its acquisition of MultiGEN Diagnostics, Inc.'s clinical laboratory assets.  Trovagene previously announced the execution of the Asset Acquisition Agreement on January 6, 2012.

Antonius Schuh, Ph.D. Joins TrovaGene, Inc. As Chief Executive Officer

SAN DIEGO--(BUSINESS WIRE)-- TrovaGene, Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, has announced that Antonius Schuh, Ph.D. has been named Chief Executive Officer. Dr. Schuh previously served as Chairman and Chief Executive Officer of Sorrento Therapeutics, Inc. (Pink Sheets: SRNE.PK), a biotechnology company he co-founded based on a proprietary platform to generate very large fully human antibody libraries. Sorrento Therapeutics merged in 2009 with a public company supported by Phillip Frost and the Frost Group.
 
Dr. Schuh also served as the founding CEO of AviaraDx, Inc., a leading molecular diagnostic innovator in oncology. In 2008, Dr. Schuh led the sale of AviaraDx to bioMerieux, which continues to operate AviaraDx under the name bioTheranostics. Before AviaraDx, Dr. Schuh served as CEO of Arcturus Bioscience, Inc., where he led the sale of Arcturus' life science business to Molecular Devices, Inc. From 2000 to 2005, Dr. Schuh served as the President and Chief Executive Officer of Sequenom, Inc. (Nasdaq: SQNM - News). He had joined Sequenom in 1996 as Managing Dierctor of its European operations, and led during his tenure, amongst others, the commercial launch of the MassARRA® system and numerous business development and corporate acquisition transactions. Dr. Schuh holds a degree in pharmaceutics and earned his Ph.D. in medicinal chemistry from the University of Bonn, Germany.
 
"We are pleased and fortunate that Dr. Schuh joins us to lead the transition of TrovaGene from a research stage organization to a commercial enterprise," states Dr. Thomas Adams, TrovaGene's Chairman. "The company has made significant efforts to establish the utility of trans-renal nucleic acids in urine as a diagnostic sample in clinical fields as diverse as detection of minimal residual disease in oncology, infectious disease, transplant medicine and prenatal monitoring. Dr. Schuh has a proven track record of building companies and creating value for shareholders. I look forward to working with him."
 
"I have observed TrovaGene closely over the past years, as I have been intrigued by the attractive opportunities the Company's proprietary trans-renal technologies offer, and I am confident that we can introduce novel diagnostic modalities with significant clinical utility based on this platform," states Dr. Schuh.

TROV executives
TROV board


Targeted $40 Billion market space:
TROV market space



TROV
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TROV News: Trovagene Announces Three New Nominees for Election to Board of Directors 03/05/2020 08:15:00 AM
TROV News: Trovagene Announces Fourth Quarter and Full-Year 2019 Results 02/27/2020 04:15:00 PM
TROV News: Amended Statement of Ownership (sc 13g/a) 02/14/2020 02:51:04 PM
TROV News: Current Report Filing (8-k) 02/13/2020 10:01:01 AM
TROV News: Trovagene Presents Phase 2 Data Demonstrating the Ability of Onvansertib to Overcome Zytiga®-Resistance and Provide Clinical... 02/13/2020 08:00:00 AM
PostSubject
#1622   Exercise of warrants $$$/cash burn... presuming phase 3 pottsvision 03/27/20 08:10:22 PM
#1621   Solid bid support. Someone is accumulating. scotsand 03/27/20 09:32:42 AM
#1620   Nice uptick. News pending? scotsand 03/25/20 12:35:40 PM
#1619   Curious as to how you've determined that Trov DVP25 03/22/20 03:07:33 PM
#1618   DVP, it was an email reply scotsand 03/22/20 02:35:01 PM
#1617   Was this an e-mail reply to a question, DVP25 03/22/20 02:24:05 PM
#1616   scotsand stockguard 03/16/20 01:29:17 PM
#1615   “Our current clinical trials are ongoing and we scotsand 03/12/20 10:06:44 PM
#1614   Picked up more today under $1. scotsand 03/12/20 10:02:12 PM
#1613   Bought more today...patience scotsand 03/11/20 07:16:20 PM
#1612   Trovagene Announces Three New Nominees for Election to abracky 03/08/20 06:50:43 AM
#1611   Very experienced board nominees. I expect good scotsand 03/06/20 12:39:27 PM
#1610   scotsand I think the worst of the damage was stockguard 02/28/20 01:52:45 PM
#1609   Filing looks decent. Will buy some cheapies.. scotsand 02/27/20 04:43:39 PM
#1608   Like a forgetful donkey owner, I have lost scotsand 02/27/20 04:17:37 PM
#1607   PCM = Lots of Goodwill $$$ in a pottsvision 02/17/20 07:41:29 PM
#1606   Delivering on the Promise of Precision Cancer MedicineTM (PCM) stockguard 02/17/20 06:04:17 PM
#1605   pottsvision stockguard 02/17/20 05:30:58 PM
#1604   Significant reason for my investment here is the pottsvision 02/15/20 08:21:52 PM
#1603   Today the stock was and is way oversold stockguard 02/14/20 04:58:36 PM
#1602   I grabbed some more for long term today. scotsand 02/14/20 12:54:41 PM
#1601   was going to buy a chunk last night dirtydozen911 02/14/20 12:14:46 PM
#1600   Good read thanks. stockguard 02/14/20 07:09:39 AM
#1599   "it`s an out of favor play" pottsvision 02/13/20 09:17:49 PM
#1598   Only problem is not with the stock or stockguard 02/13/20 05:21:13 PM
#1597   why is this down on positive results ?? dirtydozen911 02/13/20 05:16:57 PM
#1596   This company has a drug that basically arrests pottsvision 02/13/20 01:15:16 PM
#1595   In with 600... Buyout here is triple digits pottsvision 02/13/20 11:55:20 AM
#1594   Positive news out load the boat! ssp1965 02/13/20 11:37:43 AM
#1593   * * $TROV Video Chart 02-12-2020 * * ClayTrader 02/12/20 04:15:37 PM
#1592   " in reality the stock price should be pottsvision 02/11/20 10:30:30 PM
#1591   * * $TROV Video Chart 02-11-2020 * * ClayTrader 02/11/20 05:27:07 PM
#1590   Noble Capital analyst Cosme Ordonez resumes coverage on stockguard 02/11/20 01:23:21 PM
#1589   TROV NASDAQ +17% Another nice move this morning stockguard 02/10/20 02:12:20 PM
#1588   Yes, their fund will. stockguard 02/07/20 06:11:08 PM
#1587   What will this mean, she'll have stronger voting rights? viewmont 02/07/20 06:00:54 PM
#1586   She runs the Bigger Capital Fund GP, LLC stockguard 02/07/20 05:53:36 PM
#1585   TROV at BUY! https://www.tradingview.com/symbols/NASDAQ-TROV/technicals/ viewmont 02/07/20 05:46:10 PM
#1584   $23.00 (1156.83% Upside) viewmont 02/07/20 05:39:33 PM
#1583   TROV Stock Forecast and Technical Analysis viewmont 02/07/20 05:38:31 PM
#1582   This should help move the stock a bit. viewmont 02/07/20 05:05:18 PM
#1581   Is that a big share holder I guess viewmont 02/07/20 05:02:49 PM
#1580   Yesterday Patricia Winter just filed a "Statement of stockguard 02/07/20 04:28:01 PM
#1579   TROV should be moving up! Trovagene to Present viewmont 02/06/20 03:54:03 AM
#1578   Key inflection points to watch: stockguard 02/05/20 10:06:48 AM
#1577   Trovagene to Present New Clinical Data for Onvansertib viewmont 02/05/20 09:39:55 AM
#1576   https://static3.seekingalpha.com/uploads/sa_presentations/798/50798/slides/ stockguard 02/03/20 04:53:37 PM
#1575   Trovagene Receives Approximately $1.45 Million From Exercise of abracky 01/30/20 12:31:16 PM
#1574   Onvasertib Demonstrates Effectiveness as Pan-KRAS Inhibitor with Confirmed abracky 01/30/20 12:30:53 PM
#1573   * * $TROV Video Chart 01-28-2020 * * ClayTrader 01/28/20 05:59:12 PM
PostSubject